Monopar Therapeutics
MNPR • NASDAQ
Monopar Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Chandler D. Robinson, with a market cap of $361.5M.
CEOChandler D. Robinson
Next Earnings
Upcoming earnings announcement for Monopar Therapeutics
Date
Tuesday, May 12, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.79
Earnings History
Past 12 earnings reports for Monopar Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Q4 2025 | -$0.61Est: -$0.54 | -13.0% | - | — |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.48Est: -$0.42 | -14.3% | - | — | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.35Est: -$0.48 | +27.1% | - | — | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.38Est: -$0.57 | +33.3% | - | — | 10-Q |
| Mar 31, 2025 | Q4 2024 | -$2.23 | — | - | — | 10-K |
| Nov 8, 2024 | Q3 2024 | -$0.37Est: -$0.48 | +22.9% | - | — | 10-Q |
| Aug 9, 2024 | Q2 2024 | -$0.50Est: -$0.45 | -11.1% | - | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.50Est: -$0.70 | +28.6% | - | — | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$0.60Est: -$0.75 | +20.0% | - | — | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.70Est: -$0.85 | +17.6% | - | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.80Est: -$0.90 | +11.1% | - | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.95Est: -$1.10 | +13.6% | - | — | — |